University of Texas MD Anderson Cancer Center

InterVenn Biosciences Announces that Padmanee Sharma, MD, PhD, has Joined the Company’s Board of Advisors

Retrieved on: 
Thursday, April 15, 2021

b'InterVenn Biosciences today announced that Padmanee Sharma, MD, PhD, has joined the Company\xe2\x80\x99s Board of Advisors, effective March 9, 2021.

Key Points: 
  • b'InterVenn Biosciences today announced that Padmanee Sharma, MD, PhD, has joined the Company\xe2\x80\x99s Board of Advisors, effective March 9, 2021.
  • Dr. Sharma joins the InterVenn Board of Advisors with extensive experience in basic and clinical immunology and cancer research.\nDr.
  • and Jeanette Hsu Endowed Chair in Cell Biology in the Division of Cancer Medicine at MD Anderson Cancer Center.
  • For more information about InterVenn Biosciences, please visit the company\xe2\x80\x99s website .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415005368/en/\n'

Candel Therapeutics Announces Formation of New Research Advisory Board Comprised of Multiple Prominent Scientists and Clinicians including 2018 Nobel Laureate, James Allison, Ph.D.

Retrieved on: 
Tuesday, April 13, 2021

b'Candel Therapeutics, a clinical-stage biotechnology company developing novel immune-based cancer therapeutics, today announced the initial formation of its Research Advisory Board (RAB) with the appointment of James Allison, Ph.D. (MD Anderson Cancer Center), Henry Brem, M.D.

Key Points: 
  • b'Candel Therapeutics, a clinical-stage biotechnology company developing novel immune-based cancer therapeutics, today announced the initial formation of its Research Advisory Board (RAB) with the appointment of James Allison, Ph.D. (MD Anderson Cancer Center), Henry Brem, M.D.
  • (Johns Hopkins University), Roy S. Herbst, M.D., Ph.D. (Yale University), Elizabeth Jaffee, M.D.
  • (Johns Hopkins University), Philip Kantoff, M.D.
  • (Memorial Sloan Kettering Cancer Center), and Padmanee Sharma, M.D., Ph.D. (MD Anderson Cancer Center), who will join existing scientific advisor and board member Edward Benz, M.D.

Stupid Strong Charitable Foundation Pledges $250,000 to Support Gastric Cancer Research at MD Anderson Cancer Center

Retrieved on: 
Wednesday, December 23, 2020

FORT-WORTH, Texas, Dec. 23, 2020 /PRNewswire/ --Stupid Strong Charitable Foundation is proud to contribute $250,000 to The University of Texas MD Anderson Cancer Center to support cutting-edge research in gastric cancer led by Jaffer Ajani, M.D., professor of Gastrointestinal Medical Oncology.

Key Points: 
  • FORT-WORTH, Texas, Dec. 23, 2020 /PRNewswire/ --Stupid Strong Charitable Foundation is proud to contribute $250,000 to The University of Texas MD Anderson Cancer Center to support cutting-edge research in gastric cancer led by Jaffer Ajani, M.D., professor of Gastrointestinal Medical Oncology.
  • The Cless Family Foundation was touched to make a gift after reading an article in MD Anderson's Promise magazine highlighting Stupid Strong Foundation's 2019 donation to support gastric cancer research.
  • The knowledge gained by the research team will allow MD Anderson to target the unique metabolism and pathways of gastric cancer.
  • To date, Stupid Strong has granted over $775,000 to institutions around the globe for gastric cancer research and community support.

Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center

Retrieved on: 
Tuesday, December 1, 2020

AUSTIN, Texas., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the Company), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that the University of Texas MD Anderson Cancer Center is now an active clinical trial site in its ongoing ReSPECT Phase 1 clinical trial, currently supported by the National Cancer Institute (NCI).

Key Points: 
  • AUSTIN, Texas., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the Company), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that the University of Texas MD Anderson Cancer Center is now an active clinical trial site in its ongoing ReSPECT Phase 1 clinical trial, currently supported by the National Cancer Institute (NCI).
  • We are very excited to now have the MD Anderson Cancer Center enrolling patients in the ReSPECT clinical trial, said Andrew J. Brenner, M.D., Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas, Health Services Center at San Antonio and principle investigator of the ReSPECT trial.
  • We are pleased to add Dr Weinberg and the MD Anderson Cancer Center team to our growing list of ReSPECT trial sites, said Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics.
  • Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets.

Tandy Tipps, Ph.D. to Lead Inteliquet™ Healthcare Solutions and Further Expand Cancer Center Research Consortium

Retrieved on: 
Tuesday, November 17, 2020

Inteliquet , a leading provider of intelligent technology, insights, and services for optimizing clinical trials and research, announced today the appointment of Tandy Tipps, Ph.D., to lead the companys relationships and solutions development with healthcare organizations and cancer centers.

Key Points: 
  • Inteliquet , a leading provider of intelligent technology, insights, and services for optimizing clinical trials and research, announced today the appointment of Tandy Tipps, Ph.D., to lead the companys relationships and solutions development with healthcare organizations and cancer centers.
  • Dr. Tipps, who will serve as Inteliquets Senior Vice President, Healthcare Organizations Solutions, has more than 25 years leading oncology clinical research initiatives and developing global research site networks.
  • View the full release here: https://www.businesswire.com/news/home/20201117005249/en/
    Tandy Tipps, Ph.D., Inteliquets Senior Vice President, Healthcare Organizations Solutions, will lead the companys relationships and solutions development with healthcare organizations and cancer centers.
  • Previously, she was the Administrative Director of the worlds largest Phase 1 program at UT MD Anderson Cancer Center in Houston, Texas.

MD Anderson announces fifth annual class of Andrew Sabin Family Fellows

Retrieved on: 
Thursday, November 12, 2020

HOUSTON, Nov. 12, 2020 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center has named 10 early-career faculty members to the 2020 class of Andrew Sabin Family Fellows.

Key Points: 
  • HOUSTON, Nov. 12, 2020 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center has named 10 early-career faculty members to the 2020 class of Andrew Sabin Family Fellows.
  • Andrew Sabin, of East Hampton, New York, has been a member of the MD Anderson Cancer Center Board of Visitors since 2005.
  • "We are grateful for the generosity of the Andrew Sabin Family Foundation in helping MD Anderson recruit and retain the highest caliber of young researchers through this fellowship program," said Peter WT Pisters, M.D.
  • MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Focus Fund and MD Anderson Launch Investment Fund to Support Promising Investigational Cancer Therapies in Early-Stage Clinical Trials

Retrieved on: 
Tuesday, October 20, 2020

SHREVEPORT, La., NEW ORLEANS and HOUSTON, Oct. 20, 2020 /PRNewswire/ -- The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center (MD Anderson), has launched Cancer Focus Fund, LP (Cancer Focus Fund), an oncology-focusedinvestment fund designed to support the advancement of compelling investigational cancer therapies from late preclinical development through Phase I and Phase Ib/II clinical trials.

Key Points: 
  • SHREVEPORT, La., NEW ORLEANS and HOUSTON, Oct. 20, 2020 /PRNewswire/ -- The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center (MD Anderson), has launched Cancer Focus Fund, LP (Cancer Focus Fund), an oncology-focusedinvestment fund designed to support the advancement of compelling investigational cancer therapies from late preclinical development through Phase I and Phase Ib/II clinical trials.
  • Cancer Focus Fund aims to address this unmet need by providing investments for promising cancer therapeutics together with the clinical trials expertise and infrastructure of MD Anderson.
  • "The Cancer Focus Fund is a unique investment fund that aligns the scientific and clinical expertise of MD Anderson with business experts, public financing entities and private venture capital to propel promising cancer therapies toward pivotal trials," said Ross Barrett, a founder and Managing Partner of Cancer Focus Fund.
  • The Cancer Focus Fund , LPis a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center.

Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T™)

Retrieved on: 
Thursday, October 15, 2020

Under the agreement, MD Anderson and Allogene will collaborate on the design and conduct of preclinical and clinical studies with oversight from a joint steering committee.

Key Points: 
  • Under the agreement, MD Anderson and Allogene will collaborate on the design and conduct of preclinical and clinical studies with oversight from a joint steering committee.
  • MD Anderson is one of only 51 comprehensive cancer centers designated by the National Cancer Institute (NCI).
  • MD Anderson is ranked No.1 for cancer care in U.S. News & World Reports Best Hospitals survey.
  • MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Chesapeake Urology Welcomes Three New Physicians, Expanding Specialty Services in Anne Arundel, Howard, and Montgomery Counties and Baltimore City

Retrieved on: 
Thursday, September 24, 2020

is a recognized expert in prostate cryosurgery, an outpatient curative prostate cancer procedure that he has been performing for the past 15 years.

Key Points: 
  • is a recognized expert in prostate cryosurgery, an outpatient curative prostate cancer procedure that he has been performing for the past 15 years.
  • Following his residency, Dr. Levy completed a fellowship in Urologic Oncology at the MD Anderson Cancer Center in Houston, Texas.
  • Dr. Levy sees patients at Chesapeake Urology's Hanover and Saint Agnes Hospital /Angelos Medical Pavilion offices.
  • Dr. Smentkowski earned her Bachelor of Science degree in Physiology and Neurobiology from the University of Maryland, College Park, MD.

BNBuilders Completes Innovative 'Power over Ethernet' Project for Scripps Health

Retrieved on: 
Friday, September 18, 2020

SAN DIEGO, Sept. 18, 2020 /PRNewswire/ --BNBuilders has completed San Diego's first Power over Ethernet (PoE) project at Scripps MD Anderson Cancer Center.

Key Points: 
  • SAN DIEGO, Sept. 18, 2020 /PRNewswire/ --BNBuilders has completed San Diego's first Power over Ethernet (PoE) project at Scripps MD Anderson Cancer Center.
  • BNBuilders worked with FreemanWhite, TK1SC, and numerous trade partners to complete the four-phase PoE project for Scripps MD Anderson Cancer Center.
  • The 16,500-square-foot project serves as Scripps' Pilot project for PoE connected lighting solutions.
  • Scripps Health is a private, nonprofit, integrated health system in San Diego.